Youcare Pharmaceutical's subsidiary receives FDA approval for clinical trial of YKYY018 nebulized inhalation for human parainfluenza virus infection treatment and prevention

Stock News11-12

Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) has announced that its subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. ("Youcare Kechuang"), recently received a letter from the U.S. Food and Drug Administration (FDA) approving the clinical trial application for YKYY018 nebulized inhalation for the treatment and prevention of human parainfluenza virus (HPIV) infection.

Currently, the Phase II clinical study of YKYY018 nebulized inhalation targeting RSV infection is progressing steadily.

The FDA's approval to conduct clinical trials for this candidate drug in the treatment and prevention of HPIV infection marks another important milestone following the approvals for RSV and hMPV-related clinical trial applications, further expanding the clinical development layout of YKYY018 nebulized inhalation in the field of respiratory viral infection prevention and treatment, and laying the foundation for addressing the clinical treatment needs of various respiratory viral infections in the future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment